Literature DB >> 8842108

Primaquine resistance in Plasmodium vivax.

W E Collins1, G M Jeffery.   

Abstract

Reports have appeared calling attention to what has been termed primaquine resistance in Plasmodium vivax in several geographic areas. The possibility exists that primaquine tolerant strains (often referred to as the tropical zone type from the South Pacific and Southeast Asian regions characterized by early and frequent relapses) may have become widely disseminated to areas where they had not previously existed through the widespread population mobility that has characterized the last 50 years. The appearance in the relatively recent past of strains of P. vivax, particularly from the South Pacific area, that are resistant to the 4-aminoquinolines has added a new dimension to the resistance problem. While there seems to be little evidence to date of the existence of acquired primaquine resistance in P. vivax, the possibility of its emergence in the future can certainly not be ruled out, and its timely detection and confirmation will be most important, albeit quite difficult because of the relatively covert sites of drug effect. The occurrence of relapses in P. vivax after primaquine therapy would be assumed to be the most reliable indication of resistance. Reports of the sporontocidal or gametocytocidal activity of primaquine when used alone (i.e., without concomitant administration of an effective suppressive) against a P. vivax infection have been few and inconclusive. The establishment of baselines of this activity in P. vivax might be useful in detecting and evaluating primaquine resistance in this species.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8842108     DOI: 10.4269/ajtmh.1996.55.243

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  40 in total

Review 1.  The evolution of tafenoquine--antimalarial for a new millennium?

Authors:  W Peters
Journal:  J R Soc Med       Date:  1999-07       Impact factor: 5.344

Review 2.  8-Aminoquinoline Therapy for Latent Malaria.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2019-07-31       Impact factor: 26.132

3.  Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant.

Authors:  C Yang; W E Collins; J S Sullivan; D C Kaslow; L Xiao; A A Lal
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

Review 4.  Resistance to therapies for infection by Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

5.  Efficacy of three different regimens of primaquine for the prevention of relapses of Plasmodium vivax malaria in the Amazon Basin of Peru.

Authors:  Salomón Durand; Cesar Cabezas; Andres G Lescano; Mariela Galvez; Sonia Gutierrez; Nancy Arrospide; Carlos Alvarez; Meddly L Santolalla; David J Bacon; Paul C F Graf
Journal:  Am J Trop Med Hyg       Date:  2014-04-21       Impact factor: 2.345

6.  alpha -galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria.

Authors:  G Gonzalez-Aseguinolaza; C de Oliveira; M Tomaska; S Hong; O Bruna-Romero; T Nakayama; M Taniguchi; A Bendelac; L Van Kaer; Y Koezuka; M Tsuji
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

7.  In vivo and in vitro antiplasmodial activities of some plants traditionally used in Guatemala against malaria.

Authors:  F F Franssen; L J Smeijsters; I Berger; B E Medinilla Aldana
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

8.  Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia.

Authors:  Inge Sutanto; Bagus Tjahjono; Hasan Basri; W Robert Taylor; Fauziah A Putri; Rizka A Meilia; Rianto Setiabudy; Siti Nurleila; Lenny L Ekawati; Iqbal Elyazar; Jeremy Farrar; Herawati Sudoyo; J Kevin Baird
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

9.  Meager genetic variability of the human malaria agent Plasmodium vivax.

Authors:  M C Leclerc; P Durand; C Gauthier; S Patot; N Billotte; M Menegon; C Severini; F J Ayala; F Renaud
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-24       Impact factor: 11.205

Review 10.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.